Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company that reached public markets through a SPAC business combination and operates in the immunotherapy and oncology sector. The company filed an 8-K current report with the SEC on June 3, 2025, under accession number 0001213900-25-050329, reflecting an active reporting status as a post-combination public entity. Estrella is focused on developing novel immunotherapeutic candidates targeting cancer and autoimmune conditions, placing it within the life sciences segment of the post-SPAC landscape. Visit SpacDesk and sign up for full data, filings history, and deal analytics on ESLA and hundreds of other SPAC-related companies.